SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-101673
Filing Date
2022-04-11
Accepted
2022-04-11 16:16:01
Documents
12
Period of Report
2022-04-06
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K d291982d8k.htm   iXBRL 8-K 22146
  Complete submission text file 0001193125-22-101673.txt   142799

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA kymr-20220406.xsd EX-101.SCH 2861
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE kymr-20220406_lab.xml EX-101.LAB 17996
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE kymr-20220406_pre.xml EX-101.PRE 11265
6 EXTRACTED XBRL INSTANCE DOCUMENT d291982d8k_htm.xml XML 3361
Mailing Address 200 ARSENAL YARDS BLVD., SUITE 230 WATERTOWN MA 02472
Business Address 200 ARSENAL YARDS BLVD., SUITE 230 WATERTOWN MA 02472 857-285-5314
Kymera Therapeutics, Inc. (Filer) CIK: 0001815442 (see all company filings)

IRS No.: 812992166 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39460 | Film No.: 22819839
SIC: 2836 Biological Products, (No Diagnostic Substances)